


PHARMACEUTICAL 2023

Mirum Pharmaceuticals Inc. Rank 260 of 446







PHARMACEUTICAL 2023

Mirum Pharmaceuticals Inc. Rank 260 of 446



The relative strengths and weaknesses of Mirum Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Mirum Pharmaceuticals Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 38% points. The greatest weakness of Mirum Pharmaceuticals Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 86% points.

The company's Economic Capital Ratio, given in the ranking table, is 39%, being 4.6% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	190,225
Cost of Goods Sold	0
Intangible Assets	58,954
Liabilities, Current	64,729
Liabilities, Non-Current	5,789
Other Assets	102,813
Other Compr. Net Income	-182
Other Expenses	21,041
Other Liabilities	140,351
Other Net Income	4,222
Other Revenues	77,062
Property and Equipment	914
Research and Development	106,842
Selling, General and Administrative Expense	89,066

Output Variable	Value in 1000 USD
Assets	352,906
Liabilities	210,869
Expenses	216,949
Revenues	77,062
Stockholders Equity	142,037
Net Income	-135,665
Comprehensive Net Income	-135,756
Economic Capital Ratio	39%

